Diethylstilbestrol (DES) and cancer
This information is provided by the Cancer Council NSW (external site).
Diethylstilbestrol (DES) is a synthetic form of the female hormone oestrogen first manufactured in 1938. It was prescribed in Australia in the late 1940s and 1950s, less often in the 1960s and 1970s, and was prescribed in some instances beyond 1971.
DES was primarily given to prevent miscarriage and other pregnancy complications, such as tubal pregnancy and early delivery.
Other therapeutic uses included suppression of lactation and post-menopausal syndrome.
Separately it was later used as a growth promoter in chicken, sheep and cattle.
Who was exposed to diethylstilbestrol?
- DES mothers – women who took DES while pregnant
- DES daughters and sons whose mothers took DES while they were pregnant with them.
DES and negative health effects
Although the majority of people exposed to DES will not experience any negative health effects, available research findings indicate that exposure to DES increases the risk of a number of health problems.
Adverse health effects of DES for women
Women who took DES during pregnancy have a small increased risk for breast cancer.
Women exposed to DES in utero (DES daughters) are at increased risk of:
- breast cancer – (for women over 40)
- clear cell adenocarcinoma of the vagina/cervix
- structural abnormalities in the reproductive tract
- tubal (ectopic) pregnancy
- premature birth.
Adverse health effects of DES for men
Men exposed to DES in utero (DES sons) are at increased risk of:
- abnormally small testes
- undescended testes
- non-cancerous epididymal cysts.
Adverse health effects for DES grandchildren
Research into the health of DES grandsons and granddaughters has not found conclusive evidence of an increased cancer risk except for the possibility of a heightened ovarian cancer risk in DES granddaughters.
Continued monitoring of the third generation of individuals whose grandmothers were exposed to DES during pregnancy is needed to conclusively determine whether there is an increased risk of cancer in this population group.
Managing the risk
Relevant health care providers such as general practitioners, midwives and women’s health nurses who are familiar with DES can assist people affected by DES to identify possible complications.
Women prescribed DES while pregnant and DES daughters who are over 40 are advised to follow normal screening recommendations for their age group.
They should also be breast aware by familiarising themselves with the normal look and feel of their breasts, and report any unusual breast changes to their doctor, irrespective of both the time since their most recent mammogram and the results of that mammogram.
Routine Pap testing is not an adequate gynaecological cancer screening test for DES daughters. A DES-specific pelvic examination is required annually.
The examination involves:
- a careful visual inspection and feeling with the fingers or hand of the entire vagina
- separate Pap smears from the cervix and from the surfaces of the upper vagina
- an internal pelvic examination.
DES daughters planning pregnancy should alert their clinician of DES exposure prior to conception so they can be evaluated for cervical and uterine abnormalities.
During pregnancy, DES daughters should be treated as high risk patients.
Checks for men
DES sons should regularly check for lumps or swellings on the surface of the testes and promptly report any testicular masses, blood in the urine, or genital complaints to their doctor.
Where to get help
- See your doctor
- Visit a GP after hours
- Ring healthdirect on 1800 022 222
- Phone the Cancer Council Helpline on 13 11 20
- Diethylstilboestrol (DES) was commonly prescribed from 1946 to 1971 to prevent:
- early birth delivery
- ectopic pregnancy.
- DES can cause changes to the male and female reproductive system.
- DES daughters:
- should have an annual DES examination
- over 40 should follow normal screening mammogram recommendations for their age group and be breast aware
- have a slightly increased risk of infertility
- have higher risk of pregnancy complications.
This information provided by
Cancer Council NSW
This publication is provided for education and information purposes only. It is not a substitute for professional medical care. Information about a therapy, service, product or treatment does not imply endorsement and is not intended to replace advice from your healthcare professional. Readers should note that over time currency and completeness of the information may change. All users should seek advice from a qualified healthcare professional for a diagnosis and answers to their medical questions.